Sequana Medical N.v · EURONEXT:SEQUA
Sequana Medical — De Belegger on Tour 2021
13 slides from Sequana Medical's conference presentation, Sep 20, 2021
Slide 1: Innovators in the treatment of diuretic-resistant fluid overload
De Belegger on Tour – 20 September 2021 Ian Crosbie, CEO Innovators in the treatment of diuretic-resistant fluid overload liver disease – malignant ascites – heart failure
Slide 2: Disclaimers
Disclaimers Important Notice IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Sequana Medical NV (the "Company") or any person on behalf of the Company, and any question-and-answer session t
Slide 3: Disclaimers
Disclaimers Regulatory disclaimer: • The alfapump® system has not yet received regulatory approval in the United States and Canada. Any statement in this presentation about safety and efficacy of the alfapump® system does not apply to the United States and Canada. In the United States and Canada, th
Slide 4: Why diuretic resistant fluid overload is important
Why diuretic resistant fluid overload is important • Fluid overload is a key clinical problem in many important & growing diseases • Diuretics / “water pills” are standard of care – but in many cases they stop being effective • Alternatives are limited and have significant disadvantages • We are dev
Slide 5: Focus on two products – € billion opportunities
Focus on two products – € billion opportunities alfapump® alfapump DSR® Liver Disease (NASH) in N. America Congestion due to Heart Failure > €3 Bn / year market opportunity in US(1) > €5 Bn / year market opportunity in EU & US(2) Breakthrough Device Designation POSEIDON pivotal study ongoing SAHARA
Slide 6: Refractory ascites – key complication of liver cirrhosis
Refractory ascites – key complication of liver cirrhosis Fatty liver disease / NASH is driving dramatic growth and change in attitudes to liver cirrhosis patients Viral infections (Hepatitis B & C) “Normal Life” ~5 days Decreased High mortality rate mobility & Alcoholic Liver appetite, Drainage Dise
Slide 7: alfapump® – working with the bladder
alfapump® – working with the bladder Over 850 implants and hundreds of years of patient experience Breakthrough Device Designation 7 7
Slide 8: Strong interim data from FDA pivotal study (POSEIDON)
Strong interim data from FDA pivotal study (POSEIDON) Interim data indicates we are on track to meet FDA targets for approval • Reduction of external drainage by over 90% (vs FDA target of 50%) • All of our patients had ≥ 50% reduction in external drainage (vs FDA target of 50%) • Safety in line wit
Slide 9: Diuretic-resistant congestion in heart failure
Diuretic-resistant congestion in heart failure Clear unmet need and driver of costs for heart failure patients US hospitalisations HF – annually due to ~1m 90% hospitalisations HF(3) due to fluid overload(3) c.5d Typical Annual costs of US hospital stay(4) HF-related $13bn hospitalisations(4) 40%
Slide 10: alfapump DSR® – working with the kidneys
alfapump DSR® – working with the kidneys Combining our proven alfapump platform with our DSR technology 1 Our DSR infusate administered to peritoneal cavity 2 DSR infusate extracts sodium from blood stream 3 alfapump pumps extracted sodium and DSR infusate 1 into the bladder where it is naturally ex
Slide 11: Very encouraging results of RED DESERT study
Very encouraging results of RED DESERT study Intensive therapy to restore natural ability of kidneys to manage fluid balance • Safe & highly effective management of fluid and sodium balance • Dramatic and long term improvement in diuretic response • Significant improvement in cardio-renal function T
Slide 12: Shareholders base and financial overview
Shareholders base and financial overview Ticker: SEQUA – Euronext Brussels Cash: • Cash balance €21.8 M (June 30, 2021) • Cash runway to Q2 2022 Share data: • 18.5 M shares outstanding • €120 M market cap (€6.50 / share) Analysts: • KBC Securities – Lenny Van Steenhuyse • Kempen – Ingrid Gafanhão •
Slide 13: Contact info
Contact info IR@sequanamedical.com +32 498 053579 www.sequanamedical.com